Recombinant Human Thrombopoietin
- Generic Name
- Recombinant Human Thrombopoietin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- E2E529W34D
- Background
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets. This drug is used in the treatment of thrombocytopenia.
- Indication
用于治疗实体肿瘤化疗后所致的血小板减少症，使用对象为血小板低于50×109/L且医生认为有必要升高血小板数目。
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT06525948
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 60
- Registration Number
- NCT06440824
The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- JIANYANG WANG
- Target Recruit Count
- 27
- Registration Number
- NCT05944809
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 157
- Registration Number
- NCT05583838
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳the Second Hospital of HeBei Medical University, Shijiazhuang, Hebei, China
🇨🇳North China University of Science and Technology Affiliated Hospital, Tangshan, Heibei, China
Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-03-01
- Target Recruit Count
- 165
- Registration Number
- NCT05411705
- Locations
- 🇨🇳
Anqing Municipal Hospital, Anqing, Anhui, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Huihan Wang
- Target Recruit Count
- 130
- Registration Number
- NCT05382390
- Locations
- 🇨🇳
ShengJing Hospital of China Medical University, Shenyang, Liaoning, China
Herombopag + rhTPO in Severe Immune Thrombocytopenia
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Yin Jie
- Target Recruit Count
- 90
- Registration Number
- NCT05328804
- Locations
- 🇨🇳
Jie Yin, Suzhou, Jiangsu, China
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Huihan Wang
- Target Recruit Count
- 130
- Registration Number
- NCT05258799
- Locations
- 🇨🇳
ShengJing Hospital of China Medical University, Shenyang, Liaoning, China
Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 178
- Registration Number
- NCT05217719
Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04518878
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.